Macitentan
(Opsumit)
Macitentan: a review of its use in patients with pulmonary arterial hypertension
Drugs, 07/30/2014  Review Article
Dhillon S – Current evidence suggests that macitentan is a useful treatment option for initial therapy in
patients with WHO functional class II or III pulmonary arterial hypertension (PAH), which has the potential
advantage of once–daily administration.

Treatment with macitentan 10 mg once daily significantly reduced the risk for the primary composite
endpoint of morbidity and mortality in patients with PAH (mostly WHO functional class II or III) in the large,
randomized, placebo-controlled
SERAPHIN study.
Other efficacy outcomes, including exercise capacity, haemodynamic parameters and health-related quality
of life also improved significantly with macitentan relative to placebo.
Macitentan was generally well tolerated in this study.
As with other ERAs, haemoglobin levels decreased with macitentan therapy; however, these were not
progressive and stabilized following longer-term treatment.

Macitentan: a review of its use in patients with pulmonary arterial hypertension
Drugs, 07/30/2014  Review Article
Dhillon S – Current evidence suggests that macitentan is a useful treatment option for initial therapy in
patients with WHO functional class II or III pulmonary arterial hypertension (PAH), which has the potential
advantage of once–daily administration.
Methods
This article reviews the pharmacological properties, efficacy and tolerability data relevant to the use of
macitentan in this indication.
Results
Treatment with macitentan 10 mg once daily significantly reduced the risk for the primary composite
endpoint of morbidity and mortality in patients with PAH (mostly WHO functional class II or III) in the large,
randomized, placebo-controlled SERAPHIN study.
Other efficacy outcomes, including exercise capacity, haemodynamic parameters and health-related quality
of life also improved significantly with macitentan relative to placebo.
Macitentan was generally well tolerated in this study.
As with other ERAs, haemoglobin levels decreased with macitentan therapy; however, these were not
progressive and stabilized following longer-term treatment.